Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1

Conditions

Sarcoma 13Lymphoma, Large B-Cell, Diffuse 12Sarcoma, Ewing 4Osteosarcoma 4Lymphoma, B-Cell 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neurofibrosarcoma 3Lymphoma, Non-Hodgkin 3Liposarcoma 3Hodgkin Disease 3Fibrosarcoma 3Sarcoma, Synovial 2Sarcoma, Clear Cell 2Rhabdomyosarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Nerve Sheath Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Lymphoma, Follicular 2Lymphoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Histiocytoma, Angiomatoid Fibrous 2Hemangiosarcoma 2Granuloma, Plasma Cell 2Desmoplastic Small Round Cell Tumor 2Dermatofibrosarcoma 2Chondrosarcoma, Extraskeletal Myxoid 2Burkitt Lymphoma 2

Interventions

selinexor 1pazopanib 1Zoledronic Acid 1Proton Therapy 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myoepithelioma × Ifosfamide × 1 year × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡